Locally Advanced clinical trials at UCSD
1 in progress, 0 open to eligible people
Showing trials for
PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Sorry, not currently recruiting here
This Phase 1/2 study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 (INN: rezatapopt) alone (monotherapy) and in combination with pembrolizumab in participants with advanced solid tumors containing a TP53 Y220C mutation.
La Jolla, California and other locations
Last updated: